once in Biological Technology

New Drug Application for Exenatide Once Weekly Accepted for Review by FDA

SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) today announced that the New Drug Application (NDA) for exenatide once weekly has been accepte...

Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes

SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., May 5 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) today announced that a New Drug Application (NDA) for exenatide once weekly has been submitted...

Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union

S.MAMEDE DO CORONADO, Portugal and LONDON, April 28 /PRNewswire/ -- - New Option for Treatment of Epilepsy Patients With Partial Onset Seizures Bial-Portela & CA, S.A., (S. Mamede do Coronado, Portugal, President & CEO Dr Luis Portela), and Eisai Europe Limited (London; C...

BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan

NOVATO, Calif., March 30 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that it has received a notice from the United States Patent Office reporting allowance of claims covering once daily dosing methods for Kuvan(R) (sapropterin dihydrochloride) in the tr...

Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly

Lilly to Pay Amylin $125 Million and Extend $165 Million Line of Credit to Amylin SAN DIEGO and INDIANAPOLIS, Oct. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced they have entered...

Spherics, Inc. Offers Once Daily Extended Release Formulation for Sustained and Stable Pramipexole Delivery

WELLESLEY HILLS, Mass., Sept. 2 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for the benefit of creditors, announced today that all pharmaceutical intellectual property will be sold at a sealed bid auction on October 10, 2008. Wi...

Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient

$110,000,000.00 lawsuit filed 11 Dec. 2008 ATLANTA, Jan. 11 /PRNewswire-USNewswire/ -- Cryolife, Inc., (NYSE: CRY ) the country's largest distributor of cadaver tissue has once again severely maimed an elective knee surgery patient, Michael Hohenbery, with a contaminated infected knee tis...

Theyre Back: Technology Industry Spotting Angels Once Again

CHICAGO Theyre back. In its forecast of the top 10 entrepreneurial trends for 2004, Red Herring magazine recently proclaimed: Angel investors are back funding the small start-ups that will be tomorrows giants. Angels, of course, are an important source of venture financing. The Center fo...

UW prof makes laser for scanning lots of information at once

Madison University of Wisconsin-Madison researcher Scott Sanders has discovered a way to make a laser shine in not one but a rainbow of colors, and to deliver the colors one at a time so they can be used for scanning objects. Researchers can derive information about a material based on its se...

Growth spurts

... The veil is being lifted from the once unseen world of molecular activity. Not so long ago only the final products were visible and scientists were forced to gauge the processes behind thos...

Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results

...ing the clinical and non-clinical trials that will be required for us to file an NDA for CPP-109. We will report our future product development plans once they are developed." McEnany concluded, "Catalyst, along with leading addiction clinicians across the U.S., continues to seek governmental gran...

PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan

...an one million small molecules he studied, he ultimately found 4 that protected the cells and that had profiles suitable for further drug development. once these molecules were identified, Dr. Longo formed PharmatrophiX as a biotech company in order to partner with industry. PharmatrophiX is funde...

Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305

... development of prescription drugs that target unmet medical needs. It develops its products for global registration and maximum commercial potential. once registered, the products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide deve...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

...veral studies to significantly reduce the risk of pulmonary embolism and related mortality in certain high risk patient populations. In certain cases, once the risk of an embolic event has passed, the IVC filter will be removed in a subsequent surgical procedure. We believe the Option IVC Filter may have ...

Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients

...a of the brain called the putamen. The cell bodies for these same neurons are located in a different area of the brain, called the substantia nigra. once CERE-120 is delivered to the brain, it provides stable, long-lasting expression of neurturin in a highly targeted fashion. Genzyme Corporation (Nasdaq...

Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia

...d study, radezolid was administered orally at three different doses: 300 mg once daily (QD), 450 mg QD and 450 mg twice daily (BID). This novel oxazolidinon...tudy assessed the efficacy of three doses of radezolid, administered either once or twice a day for seven to 10 days. It also evaluated the safety and toler...

Bacteria pack their own demise

... and a time bomb starts ticking. Because the toxin is more stable than the antitoxin, it is broken down more slowly by the cell's clean-up mechanisms. once the antitoxin is all gone, there is still enough toxin left to kill the bacterium. The upshot for the species is that bacteria that loses their T-A g...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

...of ANA773. Anadys plans for currently enrolled patients to continue to receive ANA773 until disease progression is observed and to conclude the trial once all patients reach this point. Webcast of Conference Call Anadys will host a conference call at 5:00 pm Eastern Daylight...

Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors

... on the protein-producing DNA of choice. Compared with current protein therapy, which may be limited due to the inherent short half-life of a protein once administered into the human body, the Company believes that the localized and sustained production of micro-quantities of DNA-driven proteins at the i...

SyntheMed Receives US Patent on Novel Polymer Technology

...The novelty of these materials is that they can be delivered to difficult to access sites in the body as a liquid through a syringe or as a spray and, once exposed to body temperature, rapidly transition to a resorbable, adherent, high viscosity gel. Thus, they are ideally suited as anti-adhesion materia...

Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria

... to respond to standard, guideline-based treatment regimens. The study will assess the safety and tolerability of ARIKACE versus placebo administered once daily for several continuous months using an investigational eFlow(R) Nebulizer System (PARI Pharma GmbH), a novel, highly efficient and portable aero...

Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009

...rength of the momentum provided by our first half results, coupled with what we now forecast to be a much stronger second half, we are very pleased to once again be increasing our full year 2009 adjusted diluted EPS guidance. At the mid-point of our new guidance range of $1.13 to $1.20, we're now project...

Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic

... development of prescription drugs that target unmet medical needs. It develops its products for global registration and maximum commercial potential. once registered, the products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide deve...

U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International

...assess the appropriate next steps and promptly communicate their intentions once a decision has been made. About Thoratec Corporation Thoratec ...th the Securities and Exchange Commission (the "SEC"). The proxy statement, once finalized, will be filed by HeartWare with the SEC and mailed by HeartWare ...

Video: New Way RA(TM) Talk Show Premieres Online for People Living With Rheumatoid Arthritis (RA)

...tients frequently share with me that living with RA can be isolating. They feel disconnected from their families, friends and the activities that they once enjoyed prior to the onset of their symptoms," said Dr. Hayes Wilson. "A program like New Way RA offers great expert advice and information for peop...

Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis

...er the six month treatment period, elagolix 150 mg once daily had minimal impact on BMD (-0.80% mean chang....66% mean change from baseline, spine). The 250 mg once daily dose, as expected, had slightly greater perc...t month six (-1.0% femur, -1.6% spine). The 150 mg once daily BMD profile in this Lilac Petal Study is con...

Patent Awarded for a New X-ray Imaging Technology with Capability Unrealized with Present Day Radiological Modalities

...to develop and ensure the quality of their products. Now animal researchers can apply the same technology to ensure that the devices function properly once they are implanted, without exposing the animal to high radiation levels. Glenbrook has pioneered the use of real-time x-ray inspection technology...

Breaking barriers with nanoscale lasers

...ader Cun-Zheng Ning, a professor in the School of Electrical, Computer and Energy Engineering in ASU's Ira A. Fulton Schools of Engineering. Lasers once were the stuff largely of science fiction. Today they are everywhere in the world of electronics. They are essential components of CD and DVD players....

Cynosure Reports Second Quarter 2009 Financial Results

...been strong. While economic uncertainty continues to hinder our domestic revenue performance, we believe we will see an improvement in our U.S. sales once credit loosens and more practitioners are able to obtain financing." "Despite the challenging environment, we remain unwavering in our commitme...

Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)

...tmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries. Amgen will commercialize the d...ies' combined commercialization activities will expand access to denosumab, once approved, to patients worldwide who are afflicted by osteoporosis and other...

SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia

...t negative symptoms of schizophrenia. Patients were initially randomized in the core study to SAPHRIS 5 to 10 mg twice daily or olanzapine 5 to 20 mg once daily for 26 weeks. In the core study, both SAPHRIS and olanzapine reduced negative symptoms over the 26-week treatment period, but the difference be...

FlowCardia, Inc. Appoints Chris Barys to Chief Operating Officer

...CROSSER Catheter which utilizes high-frequency, mechanical vibration to cross the blockage in the central lumen of the coronary or peripheral artery. once the CROSSER Catheter passes through the occlusion and a guidewire is advanced distally, physicians can then perform standard atherectomy, balloon angi...

Looking Older Than You Are May Have Little to Do With Wrinkles

...lume treatments, you can slow the aging process and allay the need for major procedures later on. It really is a 'worse begets worse' scenario because once the skin begins to lose its support system through natural collagen breakdown, a cascade effect occurs." With dozens of her patient photos an...

$10,000 ISSAC Award for Innovation Presented to MIT PhD

... alloy wire, is about that of a paper clip and shaped like a pretzel. The device is inserted in a short catheter-based procedure in a doctor's office. once implanted, the system is designed to deliver drugs into the bladder for a specific period of time. The device is removed by conventional, non-surgical...

Schering-Plough Reports Financial Results for 2009 Second Quarter

...litropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days. (Announced July 1) Extended to stage two an ongoing Phase II clinical study with vicriviroc, an investigational CCR5 anta...

Practice makes perfect -- motor memory possible for neuroprosthetic control

...e days of practice for the monkeys to master precise control of the cursor. once they did, they completed the task easily and quickly for the next two weeks...are three major features scientists associate with motor memory; stability once a motor memory is consolidated it is difficult to change, rapid recall upon...

Laser technology creates new forms of metal and enhances aircraft performance

...ng on creating technology that may enable the Air Force to create an additional kind of metal. They are able to do this by using the femtosecond laser once again to alter the surface of metal and create unique nano- and micro-scale structures on the metal. "During its brief burst, the laser unleashes ...

OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock

... CEO of OncoGenex. "It also allows us to continue our planned manufacturing readiness activities to ensure that our phase 3 trials initiate as planned once a partnership for OGX-011 is secured." This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall...

Cardium's InnerCool Therapies Business to Be Acquired By Royal Philips Electronics

...as well as the transfer of approximately $1.5 million in trade payables, is subject to customary closing conditions but is expected to close shortly. once this transaction is complete the InnerCool business will operate within Philips' Healthcare sector. (Logo: http://www.newscom.com/cgi-bin/prn...

University of Florida Shands Cancer Center Selects OnCore(r) to Support its Collaborative Research Goals

...data by September first," said Moore-Higgs. In order to accomplish this, the cancer center clinical trials office will roll-out the system first. once that group has fully rolled-out the system, the cancer center will begin reaching out to other research departments doing oncology trials throughout t...